Search Results - "Chapman, Sonya C."

Abemaciclib in combination with pembrolizumab for HR+, HER2− metastatic breast cancer: Phase 1b study by Rugo, Hope S., Kabos, Peter, Beck, J. Thad, Jerusalem, Guy, Wildiers, Hans, Sevillano, Elena, Paz-Ares, Luis, Chisamore, Michael J., Chapman, Sonya C., Hossain, Anwar M., Chen, Yanyun, Tolaney, Sara M.

“…This nonrandomized, open-label, multi-cohort Phase 1b study (NCT02779751) investigated the safety and efficacy of abemaciclib plus pembrolizumab with/without…”
Get full text

Pharmacological Probes to Validate Biomarkers for Analgesic Drug Development by van Niel, Johannes, Bloms-Funke, Petra, Caspani, Ombretta, Cendros, Jose Maria, Garcia-Larrea, Luis, Truini, Andrea, Tracey, Irene, Chapman, Sonya C, Marco-Ariño, Nicolás, Troconiz, Iñaki F, Phillips, Keith, Finnerup, Nanna Brix, Mouraux, André, Treede, Rolf-Detlef

“…There is an urgent need for analgesics with improved efficacy, especially in neuropathic and other chronic pain conditions. Unfortunately, in recent decades,…”
Get full text

Abemaciclib in Combination With Endocrine Therapy for Patients With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Phase 1b Study by Tolaney, Sara M, Beeram, Muralidhar, Beck, J Thaddeus, Conlin, Alison, Dees, E Claire, Puhalla, Shannon L, Rexer, Brent N, Burris, Howard A, Jhaveri, Komal, Helsten, Teresa, Becerra, Carlos, Kalinsky, Kevin, Moore, Kathleen N, Manuel, Allison M, Lithio, Andrew, Price, Gregory L, Chapman, Sonya C, Litchfield, Lacey M, Goetz, Matthew P

“…Cyclin-dependent kinases (CDK) 4 and 6 regulate G1 to S cell cycle progression and are often altered in cancers. Abemaciclib is a selective inhibitor of CDK4…”
Get full text

Efficacy and safety of abemaciclib alone and with PI3K/mTOR inhibitor LY3023414 or galunisertib versus chemotherapy in previously treated metastatic pancreatic adenocarcinoma: A randomized controlled trial by Chiorean, E Gabriela, Picozzi, Vincent, Li, Chung-Pin, Peeters, Marc, Maurel, Joan, Singh, Jaswinder, Golan, Talia, Blanc, Jean-Frédéric, Chapman, Sonya C, Hussain, Anwar M, Johnston, Erica L, Hochster, Howard S

“…Pancreatic ductal adenocarcinomas (PDAC) are characterized by frequent cell cycle pathways aberrations. This study evaluated safety and efficacy of…”
Get full text

IMI2-PainCare-BioPain-RCT2 protocol: a randomized, double-blind, placebo-controlled, crossover, multicenter trial in healthy subjects to investigate the effects of lacosamide, pregabalin, and tapentadol on biomarkers of pain processing observed by non-invasive neurophysiological measurements of human spinal cord and brainstem activity by Leone, Caterina, Di Stefano, Giulia, Di Pietro, Giuseppe, Bloms-Funke, Petra, Boesl, Irmgard, Caspani, Ombretta, Chapman, Sonya C, Finnerup, Nanna Brix, Garcia-Larrea, Luis, Li, Tom, Goetz, Marcus, Mouraux, André, Pelz, Bernhard, Pogatzki-Zahn, Esther, Schilder, Andreas, Schnetter, Erik, Schubart, Karin, Tracey, Irene, Troconiz, Inaki F, Van Niel, Hans, Hernandez, Jose Miguel Vela, Vincent, Katy, Vollert, Jan, Wanigasekera, Vishvarani, Wittayer, Matthias, Phillips, Keith G, Truini, Andrea, Treede, Rolf-Detlef

“…Abstract Background IMI2-PainCare-BioPain-RCT2 is one of four similarly designed clinical studies aiming at profiling a set of functional biomarkers of drug…”
Get full text

IMI2-PainCare-BioPain-RCT1: study protocol for a randomized, double-blind, placebo-controlled, crossover, multi-center trial in healthy subjects to investigate the effects of lacosamide, pregabalin, and tapentadol on biomarkers of pain processing observed by peripheral nerve excitability testing (NET) by Nochi, Zahra, Pia, Hossein, Bloms-Funke, Petra, Boesl, Irmgard, Caspani, Ombretta, Chapman, Sonya C, Fardo, Francesca, Genser, Bernd, Goetz, Marcus, Kostenko, Anna V, Leone, Caterina, Li, Thomas, Mouraux, André, Pelz, Bernhard, Pogatzki-Zahn, Esther, Schilder, Andreas, Schnetter, Erik, Schubart, Karin, Stouffs, Alexandre, Tracey, Irene, Troconiz, Iñaki F, Truini, Andrea, Van Niel, Johannes, Vela, Jose Miguel, Vincent, Katy, Vollert, Jan, Wanigasekera, Vishvarani, Wittayer, Matthias, Tankisi, Hatice, Finnerup, Nanna B, Phillips, Keith G, Treede, Rolf-Detlef

“…Few new drugs have been developed for chronic pain. Drug development is challenged by uncertainty about whether the drug engages the human target sufficiently…”
Get full text

IMI2-PainCare-BioPain-RCT3: a randomized, double-blind, placebo-controlled, crossover, multi-center trial in healthy subjects to investigate the effects of lacosamide, pregabalin, and tapentadol on biomarkers of pain processing observed by electroencephalography (EEG) by Mouraux, André, Bloms-Funke, Petra, Boesl, Irmgard, Caspani, Ombretta, Chapman, Sonya C, Di Stefano, Giulia, Finnerup, Nanna Brix, Garcia-Larrea, Luis, Goetz, Marcus, Kostenko, Anna, Pelz, Bernhard, Pogatzki-Zahn, Esther, Schubart, Karin, Stouffs, Alexandre, Truini, Andrea, Tracey, Irene, Troconiz, Iéaki F, Van Niel, Johannes, Vela, Jose Miguel, Vincent, Katy, Vollert, Jan, Wanigasekera, Vishvarani, Wittayer, Matthias, Phillips, Keith G, Treede, Rolf-Detlef

“…Abstract Background IMI2-PainCare-BioPain-RCT3 is one of four similarly designed clinical studies aiming at profiling a set of functional biomarkers of drug…”
Get full text

A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor-Positive Breast Cancer by Tolaney, Sara M, Sahebjam, Solmaz, Le Rhun, Emilie, Bachelot, Thomas, Kabos, Peter, Awada, Ahmad, Yardley, Denise, Chan, Arlene, Conte, Pierfranco, Diéras, Véronique, Lin, Nancy U, Bear, Melissa, Chapman, Sonya C, Yang, Zhengyu, Chen, Yanyun, Anders, Carey K

“…The primary objective was to evaluate intracranial objective response rate (iORR) in patients receiving abemaciclib with brain or leptomeningeal metastases…”
Get full text

Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial by Tolaney, Sara M, Wardley, Andrew M, Zambelli, Stefania, Hilton, John F, Troso-Sandoval, Tiffany A, Ricci, Francesco, Im, Seock-Ah, Kim, Sung-Bae, Johnston, Stephen RD, Chan, Arlene, Goel, Shom, Catron, Kristen, Chapman, Sonya C, Price, Gregory L, Yang, Zhengyu, Gainford, M Corona, André, Fabrice

“…Patients with HER2-positive breast cancer who have received two or more previous therapies for advanced disease have few effective treatment options. The…”
Get full text

Investigating the impact of target lesion selection on drug effect evaluation and tumour growth rate determination using tumour growth inhibition models: Example of malignant pleural mesothelioma patients treated with cisplatin alone or in combination with pemetrexed by Lombard, Aurélie, Mistry, Hitesh, Chapman, Sonya C., Gueorguieva, Ivelina, Aarons, Leon, Ogungbenro, Kayode

“…In the last update of the RECIST criteria in 2009, it was proposed that the number of target lesions to be followed over time for response-to-treatment…”
Get full text

Abemaciclib Does Not Have a Clinically Meaningful Effect on Pharmacokinetics of CYP1A2, CYP2C9, CYP2D6, and CYP3A4 Substrates in Patients with Cancer by Turner, P. Kellie, Hall, Stephen D., Chapman, Sonya C., Rehmel, Jessica L., Royalty, Jane E., Guo, Yingying, Kulanthaivel, Palaniappan

Get full text

LY3022855, an anti–colony stimulating factor-1 receptor (CSF-1R) monoclonal antibody, in patients with advanced solid tumors refractory to standard therapy: phase 1 dose-escalation trial by Dowlati, Afshin, Harvey, R. Donald, Carvajal, Richard D., Hamid, Omid, Klempner, Samuel J., Kauh, John Sae Wook, Peterson, Daniel A., Yu, Danni, Chapman, Sonya C., Szpurka, Anna M., Carlsen, Michelle, Quinlan, Tonya, Wesolowski, Robert

“…Summary Background Tumor-associated macrophages (TAMs) promote tumor growth, metastasis, and therapeutic resistance via colony-stimulating factor-1 (CSF-1),…”
Get full text

Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study by Autio, Karen A, Klebanoff, Christopher A, Schaer, David, Kauh, John Sae Wook, Slovin, Susan F, Adamow, Matthew, Blinder, Victoria S, Brahmachary, Manisha, Carlsen, Michelle, Comen, Elizabeth, Danila, Daniel C, Doman, Thompson N, Durack, Jeremy C, Fox, Josef J, Gluskin, Jill S, Hoffman, David M, Kang, Suhyun, Kang, Praneet, Landa, Jonathan, McAndrew, Philomena F, Modi, Shanu, Morris, Michael J, Novosiadly, Ruslan, Rathkopf, Dana E, Sanford, Rachel, Chapman, Sonya C, Tate, Courtney M, Yu, Danni, Wong, Phillip, McArthur, Heather L

“…Tumor-associated macrophages correlate with increased invasiveness, growth, and immunosuppression. Activation of the colony-stimulating factor-1 receptor…”
Get full text

nextMONARCH: Abemaciclib Monotherapy or Combined With Tamoxifen for Metastatic Breast Cancer by Hamilton, Erika, Cortes, Javier, Ozyilkan, Ozgur, Chen, Shin-Cheh, Petrakova, Katarina, Manikhas, Aleksey, Jerusalem, Guy, Hegg, Roberto, Huober, Jens, Chapman, Sonya C., Lu, Yi, Hardebeck, Molly C., Bear, Melissa M., Johnston, Erica L., Martin, Miguel

“…Abemaciclib is a selective cyclin-dependent kinase 4 and 6 inhibitor administered continuously for hormone receptor-positive (HR+), human epidermal growth…”
Get full text

An open label, randomized phase 2 trial assessing the impact of food on the tolerability of abemaciclib in patients with advanced breast cancer by Lim, Elgene, Boyle, Frances, Okera, Meena, Loi, Sherene, Goksu, Sema Sezgin, van Hal, Gertjan, Chapman, Sonya C., Gable, Jonathon Colby, Chen, Yanyun, Price, Gregory L., Hossain, Anwar M., Gainford, M. Corona, Ezquerra, Meritxell Bellet

“…Purpose Abemaciclib, a CDK4 & 6 inhibitor, is indicated for advanced breast cancer treatment. Diarrhea is a frequently associated adverse event of abemaciclib…”
Get full text

Impact of tumour size measurement inter-operator variability on model-based drug effect evaluation by Lombard, Aurélie, Mistry, Hitesh, Chapman, Sonya C., Gueoguieva, Ivelina, Aarons, Leon, Ogungbenro, Kayode

“…Purpose During oncology clinical trials, tumour size (TS) measurements are commonly used to monitor disease progression and to assess drug efficacy. We…”
Get full text

Aurora A-Selective Inhibitor LY3295668 Leads to Dominant Mitotic Arrest, Apoptosis in Cancer Cells, and Shows Potent Preclinical Antitumor Efficacy by Du, Jian, Yan, Lei, Torres, Raquel, Gong, Xueqian, Bian, Huimin, Marugán, Carlos, Boehnke, Karsten, Baquero, Carmen, Hui, Yu-Hua, Chapman, Sonya C, Yang, Yanzhu, Zeng, Yi, Bogner, Sarah M, Foreman, Robert T, Capen, Andrew, Donoho, Gregory P, Van Horn, Robert D, Barnard, Darlene S, Dempsey, Jack A, Beckmann, Richard P, Marshall, Mark S, Chio, Li-Chun, Qian, Yuewei, Webster, Yue W, Aggarwal, Amit, Chu, Shaoyou, Bhattachar, Shobha, Stancato, Louis F, Dowless, Michele S, Iversen, Phillip W, Manro, Jason R, Walgren, Jennie L, Halstead, Bartley W, Dieter, Matthew Z, Martinez, Ricardo, Bhagwat, Shripad V, Kreklau, Emiko L, Lallena, Maria Jose, Ye, Xiang S, Patel, Bharvin K R, Reinhard, Christoph, Plowman, Gregory D, Barda, David A, Henry, James R, Buchanan, Sean G, Campbell, Robert M

“…Although Aurora A, B, and C kinases share high sequence similarity, especially within the kinase domain, they function distinctly in cell-cycle progression…”
Get full text

Opportunities for Quantitative Translational Modeling in Oncology by Yates, James W.T., Byrne, Helen, Chapman, Sonya C., Chen, Tao, Cucurull‐Sanchez, Lourdes, Delgado‐SanMartin, Juan, Di Veroli, Giovanni, Dovedi, Simon J., Dunlop, Carina, Jena, Rajesh, Jodrell, Duncan, Martin, Emma, Mercier, Francois, Ramos‐Montoya, Antonio, Struemper, Herbert, Vicini, Paolo

“…A 2‐day meeting was held by members of the UK Quantitative Systems Pharmacology Network (<http://www.qsp‐uk.net/>) in November 2018 on the topic of…”
Get full text

Correction: A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor-positive Breast Cancer by Tolaney, Sara M, Sahebjam, Solmaz, Rhun, Emilie Le, Bachelot, Thomas, Kabos, Peter, Awada, Ahmad, Yardley, Denise, Chan, Arlene, Conte, Pierfranco, Diéras, Véronique, Lin, Nancy U, Bear, Melissa, Chapman, Sonya C, Yang, Zhengyu, Chen, Yanyun, Anders, Carey K

Get full text

A Randomized Phase I Study of Abemaciclib in Chinese Patients with Advanced and/or Metastatic Cancers by Zhang, Jian, Yang, Nong, Ji, Dongmei, Shen, Weina, Li, Wenhua, Han, Rubing, Wang, Ning, Tao, Haoxun, Chapman, Sonya C., Sykes, Amanda K., Zhang, Wanli, Hu, Xichun

“…Background Abemaciclib, a cyclin-dependent kinase 4 and 6 inhibitor, is approved in combination with endocrine therapy or as monotherapy for hormone…”
Get full text